Search

Showing total 3 results
Start Over Topic antidepressants Language english
3 results

1. Carbon Nanohorn Suprastructures on a Paper Support as a Sorptive Phase

Author

Julia Ríos-Gómez, Beatriz Fresco-Cala, María Teresa García-Valverde, Rafael Lucena, and Soledad Cárdenas

Subjects
carbon nanohorns, sorptive phase, paper, microextraction, antidepressants, Organic chemistry, QD241-441
Abstract

This article describes a method for the modification of paper with single-wall carbon nanohorns (SWCNHs) to form stable suprastructures. The SWCNHs form stable dahlia-like aggregates in solution that are then self-assembled into superior structures if the solvent is evaporated. Dipping paper sections into a dispersion of SWCNHs leads to the formation of a thin film that can be used for microextraction purposes. The coated paper can be easily handled with a simple pipette tip, paving the way for disposable extraction units. As a proof of concept, the extraction of antidepressants from urine and their determination by direct infusion mass spectrometry is studied. Limits of detection (LODs) were 10 ng/L for desipramine, amitriptyline, and mianserin, while the precision, expressed as a relative standard deviation, was 7.2%, 7.3%, and 9.8%, respectively.

Published
2018
Full Text
View/download PDF

2. Carbon Nanohorn Suprastructures on a Paper Support as a Sorptive Phase.

Author

Ríos-Gómez, Julia, Fresco-Cala, Beatriz, García-Valverde, María Teresa, Lucena, Rafael, Cárdenas, Soledad, and Samanidou, Victoria F.

Subjects
*CARBON nanohorns, *DESIPRAMINE, *ANTIDEPRESSANTS, *EXTRACTION (Chemistry), *MASS spectrometry, *CHEMICAL reactions, *MIANSERIN
Abstract

This article describes a method for the modification of paper with single-wall carbon nanohorns (SWCNHs) to form stable suprastructures. The SWCNHs form stable dahlia-like aggregates in solution that are then self-assembled into superior structures if the solvent is evaporated. Dipping paper sections into a dispersion of SWCNHs leads to the formation of a thin film that can be used for microextraction purposes. The coated paper can be easily handled with a simple pipette tip, paving the way for disposable extraction units. As a proof of concept, the extraction of antidepressants from urine and their determination by direct infusion mass spectrometry is studied. Limits of detection (LODs) were 10 ng/L for desipramine, amitriptyline, and mianserin, while the precision, expressed as a relative standard deviation, was 7.2%, 7.3%, and 9.8%, respectively. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

3. The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment

Author

Thomas G. Schulze, L. Trevor Young, Layla Kassem, Paola Piccardi, Andrea Pfennig, Caterina Chillotti, Raffaella Ardau, Paul Grof, Oliver Gruber, Michael Bauer, Ichiro Kusumi, Johannes Schumacher, Sven Cichon, Nakao Iwata, Mazda Adli, Janusz K. Rybakowski, Glenda MacQueen, Maria Del Zompo, Elise T. Bui, Susan G. Leckband, Giovanni Severino, Jordan W. Smoller, Sarah Kittel-Schneider, Sevilla D. Detera-Wadleigh, Gonzalo Laje, Norio Ozaki, Piotr M. Czerski, Andreas Reif, Takeo Yoshikawa, Ryota Hashimoto, Gustavo Turecki, Mirko Manchia, Martin Alda, Nirmala Akula, Sebastian Kliwicki, Guy A. Rouleau, Joanna Hauser, John R. Kelsoe, Johanna Sasse, Alessio Squassina, Francis J. McMahon, Rebecca Hoban, Roy H. Perlis, Takuya Masui, Sara Richardson, and Tadafumi Kato

Subjects
Paper, medicine.medical_specialty, Bipolar Disorder, Lithium (medication), medicine.drug_class, International Cooperation, Schizoaffective disorder, Antimanic Agents, 03 medical and health sciences, 0302 clinical medicine, ddc:150, medicine, Humans, Manic-depressive illness, Mood stabilizer, Antidepressants, Suicidal behavior, Genome-wide association study, Neurogenesis, Neuroplasticity, ddc:610, Bipolar disorder, Psychiatry, Biological Psychiatry, National Institute of Mental Health (U.S.), Genetics, medicine.disease, United States, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, Neuropsychology and Physiological Psychology, Mood, Phenotype, Pharmacogenetics, Lithium Compounds, Manic-depressive illness, Schizoaffective disorder, Mood stabilizer, Antidepressants, Suicidal behaviour, Genome-wide association study, Neurogenesis, Neuroplasticity, Antidepressant, Anxiety, medicine.symptom, Psychology, manisch-depressive Erkrankung, bipolare Störung, Schizoaffektive Störung, Stimmungsstabilisierer, Phasenprophylaktikum, Antidepressiva, Suizidalität, genomweite Assoziationsstudie, Neurogenese, Neuronale Plastizität, 030217 neurology & neurosurgery, Clinical psychology, medicine.drug
Abstract

For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic ‘fashions’, and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts. Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Published
2010